Tuesday, October 26, 2021: 5:00 PM-7:00 PM
Exhibit Hall (Rosen Shingle Creek)
Arbaclofen Extended-Release for the Treatment of Spasticity in Multiple Sclerosis: A Randomized, Multi-Center, Placebo-Controlled Clinical Trial (Study OS440-3004)
Daniel Kantor, MD, FAAN, FANA, Florida Atlantic University;
Samuel F Hunter, MD, PhD, Advanced Neurosciences Institute;
Mark Jaros, PhD, Summit Analytical;
Tina deVries, PhD, Osmotica Pharmaceuticals;
Darin T Okuda, MD, UT Southwestern Medical Center
The Effect of Hypnotics and Stimulants on Fatigue, Sleep, and Quality of Life Outcomes in a Multiple Sclerosis Cohort
Daniela A Pimentel Maldonado, MD, Johns Hopkins University School of Medicine;
Loulwah Mukharesh, MD, Massachusetts Eye and Ear Institute;
Chen Hu, MS, Johns Hopkins University School of Medicine;
Ellen M Mowry, MD, MCR, Johns Hopkins University School of Medicine;
Bardia Nourbakhsh, MD, Johns Hopkins University School of Medicine;
Kathryn C Fitzgerald, ScD, Johns Hopkins University School of Medicine
Arbaclofen Extended-Release for the Treatment of Spasticity in Multiple Sclerosis: An Open-Label Safety Study (Study OS440-3005)
Darin T Okuda, MD, UT Southwestern Medical Center;
Daniel Kantor, MD, FAAN, FANA, Florida Atlantic University;
Mark Jaros, PhD, Summit Analytical;
Tina deVries, PhD, Osmotica Pharmaceuticals;
Samuel F Hunter, MD, PhD, Advanced Neurosciences Institute
Identifying and Characterizing Fatigue in Patients Diagnosed with Multiple Sclerosis on Disease-Modifying Therapies Using Real World Evidence
Thomas P. Leist, MD, Division of Clinical Neuroimmunology, Jefferson University;
Michele Cole, PharmD, MS, Janssen Pharmaceuticals;
Hoa Le, PhD, Janssen Pharmaceuticals;
Sumit Verma, BPharm, MS, StatInMed;
Alex Keenan, MS, Janssen Pharmaceuticals
Is a Light Hand on the Wheels Enough? Postural Sway in Standing with Different Methods of Walker Use in Multiple Sclerosis and Controls
Najala Orrell, MD, University of Saskatchewan;
Pawan Kumar, PhD Student, University of Saskatchewan;
Alison Oates, PhD, University of Saskatchewan;
Joel Lanovaz, PhD, University of Saskatchewan;
Michael Levin, FRCPC, University of Saskatchewan;
Aman Saini, MD, University of Saskatchewan;
Katherine Knox, FRCPC, University of Saskatchewan
Sources of Cannabis Information and Medical Guidance Among People with Multiple Sclerosis: Narcoms Survey Results
Robert J. Fox, MD, Mellen Center for Multiple Sclerosis, Cleveland Clinic;
Amber Salter, PhD, Washington University School in St. Louis;
Gary Cutter, PhD, The University of Alabama at Birmingham;
Joshua R. Steinerman, MD, Greenwich Biosciences, Inc.;
Kate Nichol, PhD, Greenwich Biosciences, Inc.;
Karry Smith, PhD, MPH, Greenwich Biosciences, Inc.
Arbaclofen Extended-Release for Spasticity in Multiple Sclerosis: Responder Analysis of a Phase 3 Randomized, Placebo-Controlled Clinical Study OS440-3004
Samuel F Hunter, MD, PhD, Advanced Neurosciences Institute;
Daniel Kantor, MD, FAAN, FANA, Florida Atlantic University;
James L Rogers, PhD, Summit Analytical LLC;
Tina deVries, PhD, Osmotica Pharmaceuticals;
Darin T Okuda, MD, UT Southwestern Medical Center
Symptom Burden and Treatment Goals of People with MS Spasticity: Results from SEEN-MSS, a Large-Scale, Self-Reported Survey
Scott D. Newsome, DO, MSCS, FAAN, FANA, Johns Hopkins University School of Medicine;
Ben Thrower, MD, Shepherd Center;
Barry Hendin, MD, University of Arizona;
Joanne Wagner, PT, PhD, Greenwich Biosciences;
Sherry Danese, PhD, Outcomes Insights;
Jenifer Patterson, ARNP, MSCN, Greenwich Biosciences
